You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Optimizing Care for Psoriatic Arthritis: Current Data on New and Emerging Therapeutics

  1. Bimekizumab is a novel IL-17A and IL-17F inhibitor being studied for psoriatic arthritis. BE COMPLETE, a phase 3 trial, assessed the efficacy and safety of bimekizumab 160 mg Q4W vs placebo in patients with prior inadequate response to TNFi.
    What did the study find regarding ACR50 response rates?
    They were significantly higher among patients treated with bimekizumab vs placebo
    Significant ACR50 responses with bimekizumab were not observed until week 12
    They were similar among patients treated with bimekizumab and placebo